These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 11033583)

  • 1. A small sample confidence interval approach to assess individual bioequivalence.
    Hyslop T; Hsuan F; Holder DJ
    Stat Med; 2000 Oct; 19(20):2885-97. PubMed ID: 11033583
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population and individual bioequivalence: lessons from real data and simulation studies.
    Zariffa NM; Patterson SD
    J Clin Pharmacol; 2001 Aug; 41(8):811-22. PubMed ID: 11504268
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alternative confidence intervals for the assessment of bioequivalence in four-period cross-over designs.
    Quiroz J; Ting N; Wei GC; Burdick RK
    Stat Med; 2002 Jul; 21(13):1825-47. PubMed ID: 12111892
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Case studies, practical issues and observations on population and individual bioequivalence.
    Zariffa NM; Patterson SD; Boyle D; Hyneck M
    Stat Med; 2000 Oct; 19(20):2811-20. PubMed ID: 11033577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Some statistical considerations on the FDA draft guidance for individual bioequivalence.
    Hsuan FC
    Stat Med; 2000 Oct; 19(20):2879-84. PubMed ID: 11033582
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PhRMA perspective on population and individual bioequivalence.
    Barrett JS; Batra V; Chow A; Cook J; Gould AL; Heller AH; Lo MW; Patterson SD; Smith BP; Stritar JA; Vega JM; Zariffa N
    J Clin Pharmacol; 2000 Jun; 40(6):561-70. PubMed ID: 10868305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kullback-Leibler divergence for evaluating bioequivalence.
    Dragalin V; Fedorov V; Patterson S; Jones B
    Stat Med; 2003 Mar; 22(6):913-30. PubMed ID: 12627409
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Equivalence tests for interchangeability based on two one-sided probabilities.
    Dong X; Tsong Y; Shen M
    J Biopharm Stat; 2014; 24(6):1332-48. PubMed ID: 25033074
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Individual bioequivalence testing under 2x3 designs.
    Chow SC; Shao J; Wang H
    Stat Med; 2002 Mar; 21(5):629-48. PubMed ID: 11870806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prescribability and switchability of highly variable drugs and drug products.
    Midha KK; Rawson MJ; Hubbard JW
    J Control Release; 1999 Nov; 62(1-2):33-40. PubMed ID: 10518632
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An individual bioequivalence criterion: regulatory considerations.
    Chen ML; Patnaik R; Hauck WW; Schuirmann DJ; Hyslop T; Williams R
    Stat Med; 2000 Oct; 19(20):2821-42. PubMed ID: 11033578
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A modified large sample approach in the assessment of population bioequivalence.
    Quiroz J; Ting N; Wei GC; Burdick RK
    J Biopharm Stat; 2000 Nov; 10(4):527-44. PubMed ID: 11104391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of some properties of individual bioequivalence (IBE) from replicate-design studies.
    Tothfalusi L; Endrenyi L
    Int J Clin Pharmacol Ther; 2001 Apr; 39(4):162-6. PubMed ID: 11332872
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tests for individual and population bioequivalence based on generalized p-values.
    McNally RJ; Iyer H; Mathew T
    Stat Med; 2003 Jan; 22(1):31-53. PubMed ID: 12486750
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The bootstrap in bioequivalence studies.
    Pigeot I; Hauschke D; Shao J
    J Biopharm Stat; 2011 Nov; 21(6):1126-39. PubMed ID: 22023681
    [TBL] [Abstract][Full Text] [Related]  

  • 16. On population and individual bioequivalence.
    Schall R; Luus HG
    Stat Med; 1993 Jun; 12(12):1109-24. PubMed ID: 8210816
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sample size determination for individual bioequivalence inference.
    Chiang C; Hsiao CF; Liu JP
    PLoS One; 2014; 9(10):e109746. PubMed ID: 25310592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The U.S. draft guidance regarding population and individual bioequivalence approaches: comments by a research-based pharmaceutical company.
    Hauschke D; Steinijans VW
    Stat Med; 2000 Oct; 19(20):2769-74. PubMed ID: 11033574
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The bootstrap procedure in individual bioequivalence.
    Shao J; Chow SC; Wang B
    Stat Med; 2000 Oct; 19(20):2741-54. PubMed ID: 11033572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An approach for sample size determination of average bioequivalence based on interval estimation.
    Chiang C; Hsiao CF
    Stat Med; 2017 Mar; 36(7):1068-1082. PubMed ID: 28070984
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.